Iktos has acquired AI and high-content cell imaging-based drug developer Synsight for an undisclosed amount.
Post-acquisition, Iktos plans to leverage Synsight's MT Bench technology, integrating it with Iktos Robotics, the AI-driven robotic synthesis platform developed by Iktos. This integration is expected to speed up and automate the testing of synthesized compounds, a process currently outsourced by Iktos.
T he merger will also help launch Iktos’ drug discovery programs targeting protein-protein and RNA-protein interactions, critical in diseases like cancer and neurodegenerative illnesses.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.